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Background
With improved treatment options, HIV infection has
become a well treatable disease. Nevertheless, chronic dis-
ease and toxicities of long-term therapy may impair qual-
ity of life (QoL).
Methods
Cross-sectional study (n = 209) using a self-administered
28-item-questionnaire (six scales measuring quality of
life, SEL) validated for HIV patients. For statistical analysis
non-parametric tests were used. Antiretrovirals used (>10
patients) were: lamivudine/emtricitabine 152, tenofovir
121, abacavir 32, zidovudine 30; NNRTIs: efavirenz 50,
nevirapine 28; PIs: lopinavir 31, atazanavir 17, saquinavir
12, darunavir 11.
Summary of results
Mean age 44 years; 89% male. CDC stage (1998) was A
44%, B 32% and C 24%. 80% received ART.
No difference in overall QoL between treated (3.62 ±
0.79) and untreated patients (3.66 ± 0.80) (p = 0.78) was
observed. All patients rated their physical state better
(QoL-P) (3.73 ± 0.85) than their cognitive-emotional
(QoL-CE) (3.44 ± 0.86) (p < 0.001), regardless of being
treated or not. There was no correlation between CD4+-
cells and any QoL-domain. Patients in stage CDC A had a
better QoL in all domains compared to patients with a
history of symptomatic infection CDC B or CDC C (p <
0.05).
Patients on NNRTIs reported a better QoL than patients
on PIs for QoL-P (3.91 ± 0.79 vs. 3.58 ± 0.87), QoL-CE
(3.65 ± 0.83 vs. 3.31 ± 0.89) and overall QoL (3.80 ± 0.81
vs. 3.48 ± 0.84) (all p < 0.05). However, a higher propor-
tion of patients with advanced HIV infection were treated
with PIs compared to NNRTIs: CDC A 34%/61%, CDC B
59%/42%, and CDC C 56%/40% (p < 0.05).
Overall, QoL-score was lower in HIV+ patients (3.63 ±
0.79) than in the healthy reference sample (3.81 ± 0.53)
but better than the historic HIV+ sample (3.51 ± 0.62)
from mid-1990s. Improved QoL of HIV+ patients with
and without current antiretroviral therapy compared to
patients from mid-1990s was observed in all QoL
domains.
Conclusion
HIV+ patients rate their QoL worse than healthy controls
but better than HIV+ individuals from mid-1990s. Com-
pared to HIV-negative individuals, QoL is impaired in the
cognitive-emotional domain independent of health sta-
tus. This suggests that being HIV-infected represents an
emotional stress despite improved physical well-being.
Effects of different drug classes should be interpreted care-
fully due to a potential selection bias.
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